Headlands Technologies LLC Increases Stock Position in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Headlands Technologies LLC grew its stake in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 731.3% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 90,495 shares of the biotechnology company’s stock after acquiring an additional 79,609 shares during the quarter. Headlands Technologies LLC’s holdings in Heron Therapeutics were worth $317,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in HRTX. BNP Paribas Financial Markets boosted its holdings in shares of Heron Therapeutics by 80.7% in the first quarter. BNP Paribas Financial Markets now owns 51,296 shares of the biotechnology company’s stock worth $142,000 after buying an additional 22,904 shares during the last quarter. Orchard Capital Management LLC lifted its holdings in Heron Therapeutics by 4.7% during the fourth quarter. Orchard Capital Management LLC now owns 2,243,426 shares of the biotechnology company’s stock valued at $3,814,000 after purchasing an additional 100,603 shares in the last quarter. Susquehanna Fundamental Investments LLC purchased a new position in Heron Therapeutics during the first quarter valued at approximately $32,000. State Board of Administration of Florida Retirement System lifted its holdings in Heron Therapeutics by 51.4% during the first quarter. State Board of Administration of Florida Retirement System now owns 40,705 shares of the biotechnology company’s stock valued at $113,000 after purchasing an additional 13,811 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new position in Heron Therapeutics during the second quarter valued at approximately $694,000. Hedge funds and other institutional investors own 80.01% of the company’s stock.

Heron Therapeutics Trading Up 1.6 %

Shares of NASDAQ HRTX opened at $1.87 on Friday. The firm’s 50-day moving average price is $2.43 and its 200-day moving average price is $2.80. The stock has a market capitalization of $283.62 million, a price-to-earnings ratio of -3.07 and a beta of 1.80. Heron Therapeutics, Inc. has a 12-month low of $0.50 and a 12-month high of $3.93.

Heron Therapeutics (NASDAQ:HRTX) last announced its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.02). The firm had revenue of $36.02 million for the quarter, compared to analysts’ expectations of $35.35 million. During the same quarter last year, the company earned ($0.35) EPS. On average, equities analysts predict that Heron Therapeutics, Inc. will post -0.1 EPS for the current fiscal year.

Analyst Ratings Changes

HRTX has been the topic of several analyst reports. Rodman & Renshaw initiated coverage on shares of Heron Therapeutics in a report on Thursday, June 13th. They set a “buy” rating and a $7.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $5.00 price target on shares of Heron Therapeutics in a report on Wednesday, August 7th.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.